



## DIASORIN S.P.A. STRENGTHENS THE GROUP'S R&D SENIOR MANAGEMENT TEAM

Saluggia (Vercelli), October 12, 2009 – Diasorin S.p.A., a company that operates in the global market for in vitro diagnostics, announces that, effective October 1, 2009, **Birger Jansson** joined the Diasorin Group with the title of Corporate Vice President Research & Development, a position previously held by **Antonio Boniolo**.

Mr. **Boniolo** is relinquishing his operating responsibilities, while continuing to serve as a Director and Deputy Chairman, in order to focus on supporting the Board of Directors and the Chief Executive Officer in the development of strategic decisions concerning new Group technologies.

Mr. **Birger Jansson** will lead the Research & Development Department, coordinate Worldwide Group Product Development and chair the Group's R&D Committee. He will report directly to Carlo Rosa, the Group's Chief Executive Officer.

Mr. **Birger Jansson** has an impressive scientific background and has worked at multinational corporations such as the Glaxo Group and, most recently, Cepheid Molecular Diagnostics, where he headed the European research operations.

### About Diasorin

Diasorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The Diasorin Group is comprised of 16 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including more than 100 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: [www.diasorin.com](http://www.diasorin.com)

Contacts:

**Investor Relations Officer**  
Laura Villa  
DiaSorin S.p.A.  
[laura.villa@diasorin.it](mailto:laura.villa@diasorin.it)  
+39 0161487532  
+39 348 15 11 542

**Press Office**  
Carolina Mailander  
[c.mailander@mailander.it](mailto:c.mailander@mailander.it)  
+39 335 655 56 51  
Bruno Caprioli  
[caprioli@mailander.it](mailto:caprioli@mailander.it)  
+39 335 590 14 02